Sapience ST316 β-Catenin Antagonist Peptide Shows Clean Phase 2 Safety in Metastatic Colorectal Cancer
Sapience Therapeutics presented first Phase 2 clinical data from ST316, a first-in-class β-catenin/BCL9 antagonist SPEAR peptide, in second-line metastatic colorectal cancer at AACR 2026. Dose expansion showed a well-tolerated safety profile with no dose-limiting toxicities or related SAEs, significant knockdown of Wnt-related signatures in tumor cells, and dose-proportional PK achieving predicted efficacious exposures.